RIVO-CEL TM Allogeneic Polyclonal T Cells: Intended to Improve HSCT Outcomes in the Treatment of Leukemias, Lymphomas, and Inherited Blood Disorders. RIVO-CEL allogeneic T-cell therapy incorporates our CaspaCIDe ® safety switch and is intended to improve hematopoietic stem cell transplantation (HSCT) outcomes in the treatment of hematological malignancies and inherited blood disorders. Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson 01/16/20 Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium Bellicum Pharmaceuticals Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. Events & Presentations Upcoming Events. Date. Title. 06/10/20 at 3:20 PM EDT Bellicum Pharmaceuticals Inc at Investor Summit Virtual Summer Summit 03/12/20 at 5:00 PM EDT Bellicum Pharmaceuticals 4Q and Full Year 2019 Financial Results Conference Call 11/06/19 at 5:00 PM EST Bellicum Pharmaceuticals 3Q 2019 Financial Results Conference Call 05.29.2020. Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of an
Bellicum completed the sale of its cell therapy manufacturing plant to MD Anderson on April 14. Days later, Bellicum told investors MD Anderson has temporarily stopped research, including Propelling Cellular IO Forward Bellicum is discovering and engineering high-performance product candidates in some of the most important areas of cellular immunotherapy, with a focus on chimeric antigen receptor (CAR) cell therapies, including CAR-T and CAR-NK therapies. Our pipeline of investigational immunotherapies features our costimulatory technology designed to target and treat a wide
Bellicum制药的新闻 Bellicum制药2018财年第二财季净利-2417.50万美元 同比增加1.15% 08月08日 18:38. 8月7日Bellicum制药(股票代码：BLCM)公布财报，公告显示公司2018财年第二财季净利润为-2417.50万美元，同比增长1.15%；营业收入为36.20万美元， Bellicum制药公司于2004年7月在特拉华州成立 Bellicum Houston Life Science Plaza 2130 West Holcombe Boulevard, Suite 800 Houston, Texas 77030 (832) 384-1100. Bellicum South San Francisco 611 Gateway Boulevard, Suite 820 South San Francisco, California 94080 (628) 251-5050. For Investor relations inquiries, please contact robert.uhl@westwicke.com. For Media
15 Apr 2020 April 15, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc. Purchase price of $15 million from sale of manufacturing, office and laboratory Find the latest Bellicum Pharmaceuticals, Inc. (BLCM) stock quote, history, news and other vital information to help you with your stock trading and investing.
Bellicum completed the sale of its cell therapy manufacturing plant to MD Anderson on April 14. Days later, Bellicum told investors MD Anderson has temporarily stopped research, including